| Literature DB >> 10214759 |
G P Rice1, B Paszner, J Oger, J Lesaux, D Paty, G Ebers.
Abstract
The fate of the neutralizing antibody (NAB) in MS patients treated with interferons remains unclear. We conducted a follow-up survey of NAB titers in 59 long-term treated patients from the London and Vancouver cohorts of the pivotal trial of interferon alpha-1b. NAB were measured with the myxovirus protein A assay and an ELISA, at a mean follow-up that exceeded 8 years. NAB disappeared in the majority of patients.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10214759 DOI： 10.1212/wnl.52.6.1277
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910